The UK Medicines and Healthcare products Regulatory Agency (MHRA) has a long history as a valued contributor to the global regulatory ecosystem. This contribution has been realised not only through advancements in regulatory science, but also through acting as a point of reference for the regulatory decision-making of other regulators and by leveraging outcomes from trusted partners in the system to deliver regulatory decisions and facilitate access to innovative medicines for UK patients. This balance of acting as a reference and recognising expert outputs from others is now widely accepted as standard practice and can in fact be seen as a measure of regulatory maturity. We believe that this balance should be retained as a central part of the MHRA’s operating model moving forward.
The UK’s innovative life sciences sector has called on Government to deliver policy continuity, unlock scale-up investment and improve patient access to new medicines.
Drug Discovery 2026 returns to ExCeL London from 14–15 October to celebrate 20 years of collaboration and inclusion. Keynote programme includes presentation from Dr Sam Barrell CBE and panel discussion with Dr Anne Phelan, Dr Jason Mellad, Prof Sir Mene Pangalos and Prof Raghib Ali OBE
